Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MNTX in Advanced Pancreatic Cancer
NCT04083651Phase 3Withdrawn
- Sponsor
- Valeant Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic cancer (PC) comparing MNTX Arm with Placebo Arm (2 arms). Primary endpoint: Overall Survival at Day 168. Planned start Jan 2020; status: withdrawn.
02
Drugs
methylnaltrexone
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04083651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083651.